Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Sort by: Date|Relevance

No, You Do Not Hear the Fat Lady Warming Up

Those who never predicted a financial collapse in the first place are now edging closer to the swamp to dip their toes into the water. Now they are suggesting, perhaps we could have a recession. " Forget that. You cannot have every supply chain in the world chopped in ...
Streetwise Reports | March 30, 2020 |

Biopharma Reports Consistent 'Phase 2 Liver Fat (NASH and NAFLD) Results'

The new data are reviewed and updates are provided on Can-Fite BioPharma's other clinical studies, including one for COVID-19, in this Dawson James research report. In an April 20 research note, Dawson James analyst Jason Kolbert wrote that results from Can...
Streetwise Reports | April 23, 2020 |

BioNTech, Evotec, EXMceuticals - Stocks with potential

Health is the most important thing in life. The current protective measures around the globe in connection with the spread of the Corona Virus Covid-19 show how great the fear and helplessness is. Above all, this pandemic has highlighted the extent of the global dependence on ...
Mario Hose | April 15, 2020 |

Phase 2 Data from Potential Multibagger Biopharma 'Checks All the Boxes'

The latest clinical trial results are dissected in a ROTH Capital Partners report. In a Sept. 26 research note, ROTH Capital Partners analyst Jerry Isaacson reported that AzurRx BioPharma Inc.'s (AZRX:NASDAQ) Phase 2 OPTION trial for lead candidate MS1819 in cystic ...
Streetwise Reports | October 1, 2019 |

Buzz on the Bullboards: Investor caution impacts market activity

The TSX began the week on a high note, buoyed by strength in the financial and industrial sectors. However, by Tuesday, the market had slipped into the red, as investor caution took hold ahead of the upcoming U.S. inflation data. Luckily for investors, things rebounded si...
Jonathon Brown | 10 days ago |

FDA Grants Breakthrough Status to Biopharma's Lead Candidate for Liver Disease

The California firm's most advanced asset is advancing through Phase 2b, according to a ROTH Capital Partners report. In a Feb. 19 research note, analyst Yasmeen Rahimi reported that CymaBay Therapeutics Inc. (CBAY:NASDAQ) is having a strong Q1/19 with respect to cont...
Streetwise Reports | February 26, 2019 |

From COVID to Nicotine Treatments, this Bio Stock is One to Watch

(Image via Lexaria Bioscience Corp.) There’s no shortage of excitement over potential COVID-19 vaccines. Just looking at the response to news around these developments is evidence of that, and one Company is working on a transformative, patented tech...
Stockhouse Editorial | December 1, 2020 |

Buzz on the Bullboards: New Coronavirus Opportunities

Every obstacle can be an opportunity, and the COVID-19 crisis has put the investment spotlight on companies stepping up to the plate. What we once talked about as a looming and uncertain threat has quickly become the new norm. The coronavirus pandemic has upended lives, b...
Omri Wallach | April 1, 2020 |

Siyata Mobile Still Bullish After Q2 Earnings Call

Earnings reports are useful for measuring financial milestones, but they don’t tell the whole story. Siyata Mobile (NASDAQ: SYTA, SYTAW) released their Q2 earnings on an October 15th call that included CEO Marc Seelenfreund, VP of Corporate Development Daniel...
Featured Submission | October 27, 2021 |

3 Tips for Picking Junior Gold Stocks

As the correction in gold stocks continues and as it’s likely to endure for the time being, we take a step back and share some tips for selecting individual junior gold companies. The current correction may provide the last chance to buy before the bull mar...
Jordan Roy-Byrne, CMT | October 9, 2019 |
1 2 3 4